We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry, and clinical development. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success. | Insilico Medicine is a leading generative AI-driven biotech company. Our mission is to accelerate drug discovery and development by leveraging our robust Pharma.AI platform across biology, chemistry and clinical development. With 31 programs in development including 5 clinical stage assets, our generative AI platform helps us advance the pipeline of novel drug candidates rapidly and effectively in oncology, immunology, anemia, fibrosis, COVID and others. We are actively looking for asset out-licensing and strategic biopharma partners to develop successful drugs together to help patients. In addition we have a suite of AI software tools that can be licensed for drug discovery. | We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
Immunology Consultants Laboratory, Inc.
ICL is a U.S.-based manufacturer of biochemical reagents and life science products, specializing in the production of antibodies and ELISA kits for both IVD and research applications. With over 45 years in the biotech industry, ICL has built a strong presence among the world’s leading research institutions, in vitro diagnostics (IVD) manufacturers, and biopharma companies. Backed by in-house research and development, ICL also offers custom solutions for research teams and IVD companies with needs that go beyond standard offerings. | With over 45 years of expertise, ICL is a U.S.-based manufacturer of high-quality antibodies and immunoassays serving the global life science market, including CDMOs, pharmaceutical companies, and IVD manufacturers. From our laboratory in Portland, Oregon, we produce reliable primary and secondary antibodies, ELISA kits, and host cell protein (HCP) detection assays in both human and animal models. Whether you’re developing a commercial diagnostic, optimizing a bioprocess, or conducting critical research, our reagents are designed to meet your performance standards. Explore our catalog or contact us to learn how our custom antibody and assay development services can support your next project.
iLoF
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics.
Iktos
Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in-silico, optimized to meet all key success criteria of a discovery project. Iktos combines AI-driven molecular design with robotic synthesis and biological testing, to accelerate drug discovery. With over 60 successful projects to date, Iktos supports its clients through software and strategic drug discovery collaborations. Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform. In January 2026, Iktos signed its largest Drug Discovery collaboration to date with Servier, for a total potential deal value of over €1 billion euros. For more information, visit Iktos.ai.
Hzymes Biotechnology
Hzymes Biotechnology Co., Ltd. (Hzymes) is a high-tech enterprise specializing in the research and development, production, application and technical services of enzymes. we can provide customized services for raw materials, raw material intermediates, OEM reagents. Through the optimization of key components such as enhancers, stabilizers, and preservatives, the performance of the product has been greatly improved. As a product and service supplier, we are in partnership with over 100 Chinese and international lVD reagent manufacturers, and selling the products to 25 different countries. By constantly extending our product lines, Hzymes is committed to growing into a world-class enzyme products and services supplier.
HitGen
HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. By June 30, 2022, HitGen’s DELs contains more than 1.2 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through systematic DEL compound design, HitGen DELs has involved the use of more than 6000 different types of chemical scaffolds, which includes most of the core scaffolds of currently approved small-molecule drugs and many privileged scaffolds of small-molecules in clinical trials, and the approximately 40,000 different building blocks. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com | HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. | About HitGen Inc. HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
H&T Presspart
H&T Presspart is a world leader and specialist in manufacturing drug delivery devices and pharmaceutical components. With 50 years experience in partnering with the world’s leading pharma companies we have developed a strong reputation for precision and reliability – critically important when patients’ quality of life depends on our products. Our extensive skills and experience cover drug delivery device development and industrialisation and every aspect of high-volume precision deep-drawn manufacturing, injection moulding and high-speed assembly in ISO 7 and ISO 8 cleanrooms.